Rescale, Inc.Winter 2012Active☆Watch⊞Compare

Analyst read est. — computed against this company's niche peers in the same era. Inputs shown; not a quoted figure.

No named principal in this company's public records yet — see all operators below.

Explore how these operators interlock with other companies in the operator network.

Rescale, Inc. is one of 310 Pharma companies tracked from SAN FRANCISCO, CA, USA, on record since 2011. By capital raised it ranks in the upper tier (ahead of 86% of sector peers), and among the largest by modeled valuation est..

Ranking is computed against this company's own sector cohort — reported capital is fact; valuation tiers are modeled.

AI analyst read est. — model-extracted from this company's public description, not a verified fact. 30%

operates a technology-led product inferred from public copy

Grounded in: “You are a venture analyst”

High Performance Computing Built for the Cloud

Rescale is a cloud-based platform for computational engineering and R&D, that empowers engineers and researchers to accelerate discovery, testing, and optimization. We democratize access to the latest technologies that drive greater efficiency and competitiveness, including high performance computing, simulation, modeling, AI/ML, and digital twins. The majority of industry leaders worldwide use Rescale as the backbone of R&D, connecting the digital thread of new product innovation to develop products that enrich humanity, from autonomous vehicles to drug discovery. Rescale customers include 7 of the top 10 automotive companies and 3 of the top 6 life science companies. Rescale’s full-stack, open platform automates systems, data, and workflows into a user-centric experience, so customers can focus on innovation. Choose from 1000+ pre-installed applications for multiphysics simulation and AI/ML-assisted design exploration, including commercial, open-source, and custom software. We offer the largest global network of hyperscale and specialty cloud infrastructure to leverage the latest CPU, GPU, and other specialized architectures. Rescale is enterprise-ready to enable any size organization to achieve their digital transformation goals–with unified management that gives IT teams full visibility and control of hybrid-cloud operations. Rescale’s intelligent automation gives customers flexibility to improve performance and reduce costs of computing, while our enhanced security and compliance ensures industry-leading standards are met from end to end. Getting started is simple, flexible, and free to try. Our team of experts is ready to help you achieve your most ambitious engineering goals – schedule a demo today. Join us and help us build products that change the world: www.rescale.com/careers

As reported in public records reported — not modeled.

Solid bars are reported offering amounts reported; hatched bars are the modeled post-money valuation est. — both on one shared scale so you can read raise-vs-worth at each round directly. Use the toggles to overlay data labels and the niche-peer / market average value lines.

Round size and date are reported; the stage label is inferred from round size (latest is Series B — a $15M–$40M round). Valuation is modeled from stage benchmarks scaled by the pharma sector profile. Directional, not a quoted figure.

Benchmarked against 310 companies in Pharma. Each bar is a median (the middle company, not an average — outliers don't skew it). Two yardsticks: real money raised (reported on Form D) and modeled value (our estimate est.). These are whole-sector medians across all stages, except the per-stage row.

Raised more than 86% of sector peers (real $). Modeled value above 90% of peers (estimate).

A tighter cohort than the sector chart above — only companies at the same stage (Series B) that last raised in the same ~3-year era, ranked by modeled value est. (not money raised). This is the exact set the analyst read compares against, so a like-for-like cohort is what makes "over/under-valued" meaningful. This company ranks #2 of 8.

Stage is inferred from round size est., not reported on the filing — a round's dollar size maps to a bucket: Pre-Seed <$1.0M · Seed $1.0M–$4.0M · Series A $4.0M–$15M · Series B $15M–$40M · Series C $40M–$100M · Series D+ $100M–$400M · Growth/Late >$400M.

Step-up, pace versus the sector's normal cadence, and revenue/exemption moves — read straight from the reported round facts reported.

1. Series A$11.5M2016-04-28
   • First recorded raise — entered as Series A.
   • 5 investors on this round.
2. Series B$17.4M2018-02-16
   • Raised 22 mo later, in step with the ~16 mo sector norm.
   • Round 1.5× larger than the prior — scaling up.
   • 8 investors on this round.
3. Series B$29.3M2020-01-09
   • Raised 23 mo later, in step with the ~16 mo sector norm.
   • Round 1.7× larger than the prior — scaling up.
   • 13 investors on this round.

Predictive signals are modeled est. from this company's own cadence and step-up, plus sector benchmarks — directional, not advice. Peer set and a CSV export live in your analyst workspace.

Officers, directors and promoters named in this company's public recordsreported — the people who run it (not its investors). "Also runs" counts come from name-matching across all records, so verify before acting.

Rescale, Inc. is an official record sourced from the U.S. Securities and Exchange Commission (SEC). U.S. data is aggregated from SEC Form D filings.

Nearest neighbours across the whole database — matched on sector, stage and capital scale, and on shared operators (officers or directors named at both companies in public filings). A discovery shortlist, not a valuation cohort — verify before acting, the same way modeled figures are directional.

Matched by meaning, not labels — a local language model reads each company's name, sector and description and ranks the closest in that learned space. This catches look-alikes that cross sector boundaries; the structured list above explains its matches, this one trusts the text. Directional, like every modeled signal here.

See where Rescale, Inc. sits in the wider market — its sector, location and stage cohorts, each with their own leaderboards and capital-flow timelines.

If you work at Rescale, Inc., claim this profile or suggest a correction. We aggregate from public filings, so help us keep your description, website and links accurate.